Compare INTS & DLXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INTS | DLXY |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 13.9M |
| IPO Year | 2023 | 2025 |
| Metric | INTS | DLXY |
|---|---|---|
| Price | $0.51 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.33 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 31.1K |
| Earning Date | 11-06-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $314,916,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.42 |
| Revenue Growth | N/A | ★ 8.90 |
| 52 Week Low | $0.19 | $0.64 |
| 52 Week High | $3.17 | $7.16 |
| Indicator | INTS | DLXY |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | N/A |
| Support Level | $0.35 | N/A |
| Resistance Level | $0.42 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 88.83 | 0.00 |
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.